CLINICAL_TRIALS
trial_result
· 2020-06-17
Clinical Trial Update: Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) [Phase 3]
Summary
A Phase 3 clinical trial assessing the efficacy and safety of adjunctive pimavanserin for schizophrenia has completed and results were posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2020-06-17